MLXIPL and hyperlipidemia: To illuminate the molecular mechanism by which DNJ suppresses hyperlipidemia, we evaluated regulations of DNJ on the transcription of hepatic genes involving in lipid biosynthesis (SREBP1c, FAS, ACC, GPAT, SCD, ChREBP, SREBP2, and HMGR), transport (FATP, FABP, LXR, and CD36) and oxidation (CPT1, PPARα, AMPK, and ACO).